ClinicalTrials.gg
RecruitingNCT06346080MAGECmultiDiCEUpdated Feb 18, 2026

Molecular Analysis for Gastro-Esophageal Cancer: Multicenter Discrete Choice Experiment

An interventional study of Survey in Esophageal Cancer and Gastric Cancer, sponsored by KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by KU Leuven · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,200
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Esophageal Neoplasms with a site in Belgium — 17 open to participants now, 22 under way, 5 of them phase 3. Esophageal Neoplasms · Belgium.

Planned enrollment
Largest of 32
2,200 · median 198
Started
2024
with 6 others
No phase
11 of 41
7 open now
Primary completion
2026-08
later than 6 of 21 live
Registered
36th of 41
by date
Lead sponsor
3 of 41
KU Leuven

Among the 41 studies in Esophageal Neoplasms with a site in Belgium, this one has the largest planned enrollment of the 32 interventional ones that give a count, is one of 7 that started in 2024, is one of 11 with no phase, reaches primary completion later than 6 of the 21 other live ones, and was the 36th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

17 of the 41 studies in Esophageal Neoplasms with a site in Belgium are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Esophageal Neoplasms with a site in Belgium, or all of them as a file.
02

Study summary

The goal of this survey is to investigate the participants' preference for a specific screening/diagnostic tool to detect and assess gastro-esophageal cancer.

The main question it aims to answer are:

  • Which diagnostic modality is preferred by patients and the general population?
  • Which features of the diagnostic test are most detrimental in the decision-making for one or the other modality?
  • Are geographical differences present in regard to the preference for a diagnostic modality?

Participants will be asked to complete a survey of 20-25min, including a brief intake regarding their socio-economic status. This approach will allow us to correct for confounding factors.

03

Conditions studied

  • Esophageal Cancer
  • Gastric Cancer

Keywords

  • Esophageal cancer
  • Survey
  • Gastric cancer
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Individuals >18yo to 75yo (upper age limit of Barrett's surveillance)
  2. Access to computer or smartphone
  3. Clear understanding of available languages of the experiment (English, French, Dutch, Spanish, German, Chinese, Japanese)

Exclusion criteria

Exclusion Criteria:

  1. Individuals less than 18yo and more than 75yo
  2. Incarcerated individuals
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,200 participants (estimated)

Study arms

  • Experimental
    Survey participants

    Participants who will complete a survey investigating their preference for diagnosis and assessment of gastro-esophageal cancer

    Other: Survey

Interventions

  • OtherSurvey

    Discrete choice survey

06

What researchers measure

Primary outcomes

  1. The rate of contribution of diagnostic features to the preference of participants

    A part-worth analysis, expressed as percentage, from a discrete choice experiment (questionnaire) will assess the features that are most important to the participants

    Time frame: 2 years

  2. The percentage differences in preference of participants between geographical regions

    Differences in preferences will be compared between different geographical regions using chi-squared or McNemar's test

    Time frame: 2 years

Secondary outcomes

  1. Assess the rate patient-level demographics influence the importance of a test feature, expressed as an odds ratio

    Assess the influence of demographic characteristics on the decision-making process using a multivariable logistic regression model, providing odds ratios.

    Time frame: 2 years

  2. Assess the rate of trade-off demonstrated as odds ratio between cancer-related mortality reduction and costs

    Based on an anticipated cancer detection and cost, we will assess the willingness-to-pay using a multivariable logistic regression, providing odds ratios.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data will be made available upon reasonable request with the principal investigator

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Aug 2026, 24 months after the start.

Of 209 non-industry interventional studies with no phase under Esophageal Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 94. This study's planned 24 months is below that.

Counting every sponsor, half of 218 studies reached it within 46 months; a quarter within 23 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2024
First posted
Apr 3, 2024
StartActual
Aug 1, 2024
Primary completionEst.
Aug 1, 2026
CompletionEst.
Aug 1, 2026
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06346080
Lead sponsor
KU Leuven
Responsible party
Stijn Vanstraelen (Principal investigator, KU Leuven) — Principal investigator
First posted
Apr 3, 2024
Start date
Aug 1, 2024
Primary completion
Aug 1, 2026 (estimated)
Completion
Aug 1, 2026 (estimated)
Last update
Feb 18, 2026

Study contacts

Stijn Vanstraelen, MD
Contact
stijn.vanstraelen@kuleuven.be
16346822 ext. 0032
Stijn Vanstraelen, MD
principal investigator · UZ Leuven
Philippe Nafteux, MD, PhD
principal investigator · UZ Leuven

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion